BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.62 USD
-0.02 (-3.18%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $0.62 +0.01 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 1 - 20 ( 110 total )
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Topline Beat; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 At-Home Setting Pivotal Program Design Parameters; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TRANQUILITY Pivotal Trial Plan; Equity Financing; Adjusting PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Trial Program Clarity; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dexmedetomidine Oromucosal Formulation Patent Allowance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Virtual Neuroscience RD Day Showcases Neurology Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Clinical Pathway Clarified; Debt Agreements Updated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NIDA Requests Opioid Use Disorder Trial Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IGALMI Assigned Permanent J-Code; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TRANQUILITY II Data Integrity Affirmed in Third Party Audit; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL701 Phase 2 Prostate Cancer Data Prove Positive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sublingual Dexmedetomidine Patent Estate Strengthened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 TRANQUILITY Program Type B Meeting Scheduled; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Commercial Strategy Retooled; 2Q23 Financials; Lowering PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive TRANQUILITY II Data Marred by Reporting Issues; Lowering PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 SERENITY III Part 1 Data Look Favorable, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Phase 1 Trial Data Proves Positive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Top and Bottom-Line Miss, But All Eyes on Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
IGALMI Slow Burn Likely; 2022 Financials; Lowering PT to $66
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R